Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170078 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment
A Phase 1 study, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT01170078 is a Phase 1 study that has completed, run by Hospira, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 107 participants.
The verdict
NCT01170078, a Phase 1 study, has completed, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This study assessed the comparability of the pharmacokinetics (PK) of epoetin following intravenous administration of Hospira Epoetin and Epogen/Epoetin Alfa (Amgen) in patients with chronic renal failure receiving hemodialysis treatment.
Interventions
- DRUG Epoetin Hospira
- DRUG Epogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170078
The ClinicalTrials.gov registry entry for NCT01170078 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Hospira is the first listed.
NCT01170078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01170078 about?
NCT01170078 is a clinical study titled "A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment". This study assessed the comparability of the pharmacokinetics (PK) of epoetin following intravenous administration of Hospira Epoetin and Epogen/Epoetin Alfa (Amgen) in patients with chronic renal failure receiving hemodialysis treatment.
What is the current status of trial NCT01170078?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2010-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01170078?
The interventions under investigation include: Epoetin Hospira (DRUG), Epogen (DRUG).
Who is sponsoring clinical trial NCT01170078?
This trial is sponsored by Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.